NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Core Insights - NeOnc Technologies Holdings, Inc. has appointed David Choi as Chief Accounting Officer to oversee accounting, financial reporting, internal controls, and corporate governance as the company advances its clinical-stage biotechnology platform and expands globally [1][2] Company Overview - NeOnc Technologies is a clinical-stage life sciences company focused on developing and commercializing central nervous system therapeutics, particularly targeting challenges in overcoming the blood-brain barrier [5] - The company's NEO™ drug development platform has produced a portfolio of novel drug candidates with patent protections extending to 2038, including proprietary chemotherapy agents that have shown positive effects in laboratory tests and clinical trials for malignant gliomas [5] - NeOnc's therapeutics, NEO100™ and NEO212™, are currently in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status [5] Leadership Appointment - David Choi brings over a decade of experience in accounting, financial reporting, and internal controls for public and private companies, having previously served as a Director at Blythe Global Advisors [2][3] - His expertise includes technical accounting matters, SEC reporting, and SOX compliance, which are crucial as NeOnc accelerates its clinical trials and prepares for corporate growth [2][3] - Choi is a Certified Public Accountant (CPA) with a Master of Professional Accountancy and a Bachelor of Arts in Business Economics with a minor in Accounting from the University of California, Irvine [4]